ORLANDO, Fla., May 14, 2015 /PRNewswire/ -- MEDITE Cancer
Diagnostics, Inc., ("Company," OTCQB symbol: "MDIT") specializing
in the development, manufacturing and marketing of molecular
biomarkers and premium medical devices for detection, risk
assessment and diagnosis of cancer and precancerous
conditions, announces change of auditors.
Logo - http://photos.prnewswire.com/prnh/20150514/216188LOGO
On May 13, 2015, upon the
recommendation of the Company's Audit Committee, the Board of
Directors of the Company engaged WithumSmith+Brown, P.C. ("WSB") as
the Company's independent registered public accounting firm,
beginning with the period ended March 31,
2015. WSB is one of the largest accounting firms in the
Northeast, and one of the top 31 accounting firms in the U.S. The
Firm has a staff of approximately 500, with more than 350
professionals and almost 250 CPAs.
After the acquisition of MEDITE Enterprise, Inc. by the former
CytoCore, Inc. in 2014 the Company moved its headquarters from
Chicago, Ill. to Orlando, Fla. The engaged audit firm has a
local office in Orlando which is
an important factor for efficient audit work.
One day before on May 12, 2015,
upon the recommendation of the Company's Audit Committee, the Board
of Directors of MEDITE Cancer Diagnostics, Inc. (the "Company")
dismissed L.J. Soldinger Associates ("LJSA") as the Company's
independent auditing firm. The dismissal was without disagreement
and we thank Soldinger Associates for 8 years of audit work for the
Company.
About MEDITE Cancer Diagnostics, Inc.:
MEDITE Cancer Diagnostics, Inc., is a Delaware registered company consisting of
wholly-own MEDITE GmbH, a Germany-based company, with its subsidiaries
CytoGlobe GmbH (Germany), MEDITE
GmbH (Austria), MEDITE Inc.
(USA) and MEDITE sp. z o.o.
(Poland). Since 1978, MEDITE has
specialized in the development, manufacture and distribution of
medical laboratory automation equipment and supplies for pathology,
histology and cytology. For these fields, MEDITE with its 76
employees offers a complete range of devices and consumables
through an established distribution network to about 70 countries.
Additional information on MEDITE's products and services can be
found at www.medite-group.com. On April 3,
2014, MEDITE was acquired by CytoCore, Inc. a bimolecular
diagnostics company engaged in the design, development, and
commercialization of cost-effective cancer screening systems and
Biomarkers to assist in the early detection of cancer. The name of
the company changed from CytoCore, Inc. to MEDITE Cancer
Diagnostics, Inc. in early December
2014.
For more information please visit: http://www.medite-group.com/
Investor Contact:
Robert McCullough, Jr. CFO
407-996-9630
*LOGO (web):
Send2Press.com/mediaboom/15-0514-medite-500x375.jpg
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/medite-cancer-diagnostics-inc-announces-change-of-auditor-300083884.html
SOURCE MEDITE Cancer Diagnostics, Inc.
